This condition is known as insulin resistance, which is a major problem for people with type 2 diabetes. It helps the body move sugar (glucose) from the blood into the cells, where it is used for energy. Testosterone Replacement Therapy may help improve insulin sensitivity, reduce fat mass, and improve the overall health of men with both low T and diabetes. TRT can increase the number of red blood cells in the body, which can lead to a condition called polycythemia. Since people with diabetes already have a higher risk of heart disease, this is an important consideration. Some studies have suggested that TRT might raise the risk of heart attacks or strokes, particularly in older men or those with existing heart conditions. We have shown that TRT improves IR and glycemic control in hypogonadal men with diabetes. We observed in which group we had the best outcomes and after 6 months of treatment we repeated the diagnostic assessments. In the first group, existing antidiabetic therapy remained unchanged, but diet, physical activity and TRT were added. Pearson’s (r) correlation tests were used to determine the relationship between study parameters, depending on variable distribution. This article aims to help readers understand the connection between low testosterone and diabetes. Research has shown that low testosterone and type 2 diabetes are closely linked. Low testosterone, also called low T, is a condition where the body doesn’t produce enough testosterone, the primary male hormone. In thirteen studies, testosterone recipients had lower total cholesterol levels than placebo recipients. Furthermore, testosterone supplementation improved metabolic syndrome biomarkers, such as insulin sensitivity, as evidenced by lower HOMA-IR, higher HOMA%, and lower blood C-peptide and proinsulin levels . This comprehensive systematic review and meta-analysis of 15 studies comprising 3002 patients investigated the effects of testosterone replacement treatment in hypogonadal males with type 2 diabetes compared to the control group (T2DM). This meta-analysis offers the most up-to-date look at how testosterone therapy compares to no treatment or placebo, as far as we are aware. Multiple studies have demonstrated that testosterone replacement therapy (TRT) significantly reduces fasting serum glucose (FSG), fasting serum insulin (FSI), and hemoglobin A1C (HBA1C) in hypogonadal patients with type 2 diabetes . However, the benefits of testosterone therapy take longer than this to appear and other studies have excluded the first 3 months treatment from analysis due to the likelihood of events relating to the pre-existing condition. If a patient's first test is At this time, there is no definitive evidence indicating what the optimal time interval should be between the two separate tests. The Panel urges clinicians to use their clinical judgment in the management of such patients. Although direct measurement of free testosterone has a generally good correlation with equilibrium dialysis, it is not reliable because of high CV. This is based on the concept that the free testosterone fraction is believed to be the most biologically active component. The most accurate testosterone measurements are obtained in the early morning and on more than one occasion, which is not uniform across testosterone trials. However, practicing clinicians who review testosterone lab results will commonly face the dilemma of whether to use the reference ranges published by their specific lab or the absolute measure itself. Laboratories that perform testosterone assays that have a CV that falls within ±6.4 % of samples tested by the CDC (with testosterone values ranging from 2.5-1,000 ng/dL) are certified. Diagnosing low testosterone in diabetic men can be tricky because many symptoms of low T overlap with diabetes symptoms. Low testosterone can increase the risk of fractures or other bone-related issues. Diabetic men are already at risk of bone health problems due to complications from diabetes, such as poor circulation or nerve damage. Low testosterone can also contribute to ED, making it hard to figure out if the problem is due to diabetes, low T, or both. Thus, in this case, in order to evaluate the insulin-sensitizing response of testosterone, a prolonged OGTT was performed with glucose and insulin measurements at 0, 30, 60, 120, 180 and 240 minutes before and after the administration of TU. In addition, complete remission of DM2, risk reduction of cardiovascular disease and mortality was reported with TU treatment 25–28. Our patient had several cardiovascular risk factors, including HTN, DM2, DLD and obesity, the most commonly reported comorbidities in patients with this type of karyotypic abnormality. Men with KS have an increased mortality risk, probably due to their higher predisposition to develop congenital malformations, cardiovascular disease and endocrine-metabolic disorders, compared to age-matched controls . Vildagliptin was discontinued and the patient was asked to undergo a prolonged oral glucose tolerance test (OGTT) with blood glucose measurements at various timepoints, prior to and 48 hours after the next administration of testosterone.
